I

Intercept Pharmaceuticals Inc
F:I4P

Watchlist Manager
Intercept Pharmaceuticals Inc
F:I4P
Watchlist
Price: 17.52 EUR Market Closed
Market Cap: 732.8m EUR
Have any thoughts about
Intercept Pharmaceuticals Inc?
Write Note

Intrinsic Value

I4P's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one I4P stock under the Base Case scenario is 26.73 EUR. Compared to the current market price of 17.52 EUR, Intercept Pharmaceuticals Inc is Undervalued by 34%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

I4P Intrinsic Value
26.73 EUR
Undervaluation 34%
Intrinsic Value
Price
I
Worst Case
Base Case
Best Case

Valuation Backtest
Intercept Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for I4P cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about I4P?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Intercept Pharmaceuticals Inc

Provide an overview of the primary business activities
of Intercept Pharmaceuticals Inc.

What unique competitive advantages
does Intercept Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does Intercept Pharmaceuticals Inc face in the near future?

Summarize the latest earnings call
of Intercept Pharmaceuticals Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Intercept Pharmaceuticals Inc.

Provide P/S
for Intercept Pharmaceuticals Inc.

Provide P/E
for Intercept Pharmaceuticals Inc.

Provide P/OCF
for Intercept Pharmaceuticals Inc.

Provide P/FCFE
for Intercept Pharmaceuticals Inc.

Provide P/B
for Intercept Pharmaceuticals Inc.

Provide EV/S
for Intercept Pharmaceuticals Inc.

Provide EV/GP
for Intercept Pharmaceuticals Inc.

Provide EV/EBITDA
for Intercept Pharmaceuticals Inc.

Provide EV/EBIT
for Intercept Pharmaceuticals Inc.

Provide EV/OCF
for Intercept Pharmaceuticals Inc.

Provide EV/FCFF
for Intercept Pharmaceuticals Inc.

Provide EV/IC
for Intercept Pharmaceuticals Inc.

Show me price targets
for Intercept Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for Intercept Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for Intercept Pharmaceuticals Inc?

What are the Net Income projections
for Intercept Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for Intercept Pharmaceuticals Inc?

What are the EPS projections
for Intercept Pharmaceuticals Inc?

How accurate were the past EPS estimates
for Intercept Pharmaceuticals Inc?

What are the EBIT projections
for Intercept Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for Intercept Pharmaceuticals Inc?

Compare the revenue forecasts
for Intercept Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Intercept Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Intercept Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Intercept Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of Intercept Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Intercept Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of Intercept Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for Intercept Pharmaceuticals Inc.

Provide ROE
for Intercept Pharmaceuticals Inc.

Provide ROA
for Intercept Pharmaceuticals Inc.

Provide ROIC
for Intercept Pharmaceuticals Inc.

Provide ROCE
for Intercept Pharmaceuticals Inc.

Provide Gross Margin
for Intercept Pharmaceuticals Inc.

Provide Operating Margin
for Intercept Pharmaceuticals Inc.

Provide Net Margin
for Intercept Pharmaceuticals Inc.

Provide FCF Margin
for Intercept Pharmaceuticals Inc.

Show all solvency ratios
for Intercept Pharmaceuticals Inc.

Provide D/E Ratio
for Intercept Pharmaceuticals Inc.

Provide D/A Ratio
for Intercept Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for Intercept Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for Intercept Pharmaceuticals Inc.

Provide Quick Ratio
for Intercept Pharmaceuticals Inc.

Provide Current Ratio
for Intercept Pharmaceuticals Inc.

Provide Cash Ratio
for Intercept Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for Intercept Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for Intercept Pharmaceuticals Inc?

What is the current Free Cash Flow
of Intercept Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Intercept Pharmaceuticals Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Intercept Pharmaceuticals Inc

Current Assets 383.4m
Cash & Short-Term Investments 322.7m
Receivables 32.5m
Other Current Assets 28.3m
Non-Current Assets 9.7m
PP&E 5.8m
Other Non-Current Assets 3.9m
Current Liabilities 90.8m
Accounts Payable 10.3m
Accrued Liabilities 39m
Other Current Liabilities 41.6m
Non-Current Liabilities 230.5m
Long-Term Debt 223.9m
Other Non-Current Liabilities 6.6m
Efficiency

Earnings Waterfall
Intercept Pharmaceuticals Inc

Revenue
317.7m USD
Cost of Revenue
-632k USD
Gross Profit
317.1m USD
Operating Expenses
-372.1m USD
Operating Income
-55.1m USD
Other Expenses
-6.5m USD
Net Income
-61.6m USD

Free Cash Flow Analysis
Intercept Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

The company looks forward to Ocaliva's continued growth into the next year and expects a revenue range of $3.20 to $3.40 billion despite not providing explicit guidance. They have achieved four consecutive quarters of growth and project cost savings of $140 million, estimating next year's expenses between $3.50 to $3.70 billion. This includes a Phase 3 study for a fixed dose combination. Ocaliva's pricing strategy remains undisclosed, but a recent 5.9% price increase followed the product's value. Enrollment in European studies faced pandemic-related slowdowns, but the Phase 3 program is gaining momentum due to the excitement within therapeutic areas. Persistence rates for Ocaliva show over 50% of patients continue usage after two years, with pruritus (itching) mostly mild to moderate and manageable.

What is Earnings Call?
Fundamental Scores

I4P Profitability Score
Profitability Due Diligence

Intercept Pharmaceuticals Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
ROIC is Increasing
Positive 1-Year Revenue Growth
Positive 3-Years Revenue Growth
24/100
Profitability
Score

Intercept Pharmaceuticals Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

I4P Solvency Score
Solvency Due Diligence

Intercept Pharmaceuticals Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
High D/E
45/100
Solvency
Score

Intercept Pharmaceuticals Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

I4P Price Targets Summary
Intercept Pharmaceuticals Inc

There are no price targets for I4P.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for I4P?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for I4P is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Intercept Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

732.5m EUR

Dividend Yield

0%

Description

Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Morristown, New Jersey and currently employs 437 full-time employees. The company went IPO on 2012-10-11. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic steatohepatitis (NASH), OCA and Bezafibrate, and Other Product Candidates. The Company’s marketed product, Ocaliva, is a farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. The firm is evaluating tolerability of OCA in combination with bezafibrate in patients with PBC in a Phase II study outside of the United States. The Company’s other compounds are in early stages of research and development pipeline, including INT-787 compound, an FXR agonist is in a Phase I clinical trial.

Contact

NEW JERSEY
Morristown
305 MADISON AVENUE
+16467471000.0
www.interceptpharma.com

IPO

2012-10-11

Employees

437

Officers

Pres, CEO & Director
Mr. Jerome B. Durso
Chief Financial Officer
Mr. Andrew Saik
Chief Accounting Officer & Treasurer
Mr. Rocco Venezia
Gen. Counsel
Mr. Jared M. Freedberg J.D.
Pres of R&D and Chief Medical Officer
Dr. M. Michelle Berrey M.D., M.P.H., MPH.
Exec. Director of Global Investor Relations
Mr. Nareg Sagherian
Show More
Chief HR Officer
Mr. David Ford
Founder, Advisor & Director
Dr. Mark Pruzanski M.D.
Exec. VP & Chief Commercial Officer
Ms. Linda M. Richardson
Sr. VP of Regulatory Affairs
Paul Nitschmann
Show Less

See Also

Discover More
What is the Intrinsic Value of one I4P stock?

The intrinsic value of one I4P stock under the Base Case scenario is 26.73 EUR.

Is I4P stock undervalued or overvalued?

Compared to the current market price of 17.52 EUR, Intercept Pharmaceuticals Inc is Undervalued by 34%.

Back to Top